Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Overview | 9 | 1 |
| Therapeutics Development | 10 | 4 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Products under Development by Stage of Development | 10 | 1 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Products under Development by Therapy Area | 11 | 1 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Products under Development by Indication | 12 | 2 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Unknown Stage Products | 16 | 1 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Products under Development by Companies | 17 | 4 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Products under Development by Universities/Institutes | 21 | 2 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Therapeutics Assessment | 23 | 7 |
| Assessment by Monotherapy/Combination Products | 23 | 1 |
| Assessment by Mechanism of Action | 24 | 2 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 2 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Companies Involved in Therapeutics Development | 30 | 19 |
| Aduro BioTech, Inc. | 30 | 1 |
| Agenus, Inc. | 31 | 1 |
| Alligator Bioscience AB | 32 | 1 |
| AlphaMab Co., Ltd | 33 | 1 |
| Bristol-Myers Squibb Company | 34 | 1 |
| Cold Genesys, Inc. | 35 | 1 |
| CytomX Therapeutics, Inc. | 36 | 1 |
| Immunocore Limited | 37 | 1 |
| JHL Biotech, Inc. | 38 | 1 |
| Lytix Biopharma AS | 39 | 1 |
| MedImmune, LLC | 40 | 1 |
| Novartis AG | 41 | 1 |
| OncoImmune, Inc. | 42 | 1 |
| Premier Biomedical Inc | 43 | 1 |
| PsiOxus Therapeutics Limited | 44 | 1 |
| Sutro Biopharma, Inc. | 45 | 1 |
| Theravectys SA | 46 | 1 |
| Tikcro Technologies, Ltd. | 47 | 1 |
| Xencor, Inc. | 48 | 1 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Drug Profiles | 49 | 44 |
| AGEN-1884 Drug Profile | 49 | 2 |
| AGEN-2041 Drug Profile | 51 | 1 |
| Antisense Oligonucleotide to Inhibit CTLA4 for Oncology Drug Profile | 52 | 1 |
| ATOR-1015 Drug Profile | 53 | 1 |
| Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor Drug Profile | 54 | 1 |
| Biologic to Antagonize CTLA4 for Solid Tumor Drug Profile | 55 | 1 |
| CG-0070IT Drug Profile | 56 | 1 |
| CG-0161 Drug Profile | 57 | 1 |
| durvalumab + IMCgp-100 + tremelimumab Drug Profile | 58 | 1 |
| durvalumab + tremelimumab Drug Profile | 59 | 4 |
| ipilimumab Drug Profile | 63 | 9 |
| JMW-3B3 Drug Profile | 72 | 1 |
| KN-044 Drug Profile | 73 | 1 |
| LTX-315 + Anti-CTLA4 Drug Profile | 74 | 1 |
| MEDI-0562 + tremelimumab Drug Profile | 75 | 1 |
| MEDI-3617 + tremelimumab Drug Profile | 76 | 1 |
| Monoclonal Antibodies to Inhibit CTLA-4 for Metastatic Melanoma Drug Profile | 77 | 1 |
| Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology Drug Profile | 78 | 1 |
| Monoclonal Antibody to Antagonize CTLA-4 for Oncology Drug Profile | 79 | 1 |
| Monoclonal Antibody to Antagonize CTLA4 for Oncology Drug Profile | 80 | 1 |
| Monoclonal Antibody to Antagonize CTLA4 for Oncology Drug Profile | 81 | 1 |
| Monoclonal Antibody to Inhibit CTLA-4 for Oncology Drug Profile | 82 | 1 |
| Monoclonal Antibody to Inhibit CTLA4 for Breast Cancer Drug Profile | 83 | 1 |
| Monoclonal Antibody to Inhibit CTLA4 for Oncology Drug Profile | 84 | 1 |
| ONC-392 Drug Profile | 85 | 1 |
| Oncolytic Viruses to Antagonize CTLA4 for Solid Tumors Drug Profile | 86 | 1 |
| Small Molecule to Target CTLA4 and IFNGR for RRMS Drug Profile | 87 | 1 |
| SNCA-21 Drug Profile | 88 | 1 |
| tremelimumab Drug Profile | 89 | 3 |
| XmAb-20717 Drug Profile | 92 | 1 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Dormant Projects | 93 | 2 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Discontinued Products | 95 | 1 |
| Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Featured News &Press Releases | 96 | 15 |
| Oct 08, 2016: Yervoy (ipilimumab) Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study | 96 | 1 |
| Sep 06, 2016: Mesothelioma Treatment Center at Baylor St. Luke s launches clinical trial of cancer combination therapy | 97 | 1 |
| Jul 27, 2016: Combining Ipilimumab with local treatments improved survival for patients with melanoma | 98 | 1 |
| Jul 13, 2016: Immunotherapy benefits relapsed stem cell transplant recipients | 99 | 1 |
| Apr 27, 2016: Agenus Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors | 100 | 1 |
| Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate AGEN2041 at the American Association for Cancer Research (AACR) 2016 Annual Meeting | 101 | 1 |
| Feb 29, 2016: AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma | 102 | 1 |
| Feb 17, 2016: Immune-targeting drug combo shows promise for lung cancer patients, says Moffitt | 102 | 1 |
| Feb 08, 2016: Astrazeneca S Combination of Durvalumab with Tremelimumab Shows Clinical Activity in Non-Small Cell Lung Cancer Irrespective Of PD-L1 Status | 103 | 1 |
| Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-CTLA-4 Antibody | 104 | 1 |
| Oct 28, 2015: Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully Resected Stage III Melanoma | 105 | 1 |
| Oct 19, 2015: Cold Genesys Announces FDA Acceptance of a Phase I/II Clinical Trial Using CG0070 Plus an Anti-CTLA-4 Checkpoint Inhibitor as a Neo-Adjuvant Immunotherapy for Muscle Invasive Bladder Cancer | 106 | 1 |
| Jun 02, 2015: AstraZeneca updates on immuno-oncology combinations development programme at ASCO 2015 | 107 | 1 |
| May 31, 2015: Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo + Yervoy Regimen or Opdivo Monotherapy vs. Yervoy Monotherapy in Previously Untreated Patients with Advanced Melanoma | 108 | 3 |
| Appendix | 111 | 2 |
| Methodology | 111 | 1 |
| Coverage | 111 | 1 |
| Secondary Research | 111 | 1 |
| Primary Research | 111 | 1 |
| Expert Panel Validation | 111 | 1 |
| Contact Us | 111 | 1 |
| Disclaimer | 112 | 1 |
